Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PFIZER INCPFE · Entity 2863 | Senior Vice President | March 13, 2009 | March 16, 2009 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PFIZER INC
Report date March 13, 2009 · Filed March 16, 2009
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock Units SSPSEC Table II · derivative / convertible security | Direct | 27,354 |
Reported balance
After 2009-03-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2009-03-13 · Grant · Acquired 951 · Balance 27,354 F1: Each unit represents one phantom share of common stock. F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. |
Filing footnotes · ownership attribution and instrument terms
F1: Each unit represents one phantom share of common stock.
F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ChemoCentryx, Inc.
Report date October 20, 2022 · Filed October 24, 2022
Section 16 reporting ended · disclosed 2022-10-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 1
1 source rowRow 1 · 2022-10-20 · Disposition to issuer · Disposed 148,127 · Balance 0 F1: Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Shares," and each such share, a "Share") (other than any such Shares (i) held by the Company as treasury stock or owned by Parent or Merger Sub, (ii) held by any subsidiary of the Company or Parent (other than Merger Sub) or (iii) as to which appraisal rights have been properly exercised, F2: (Continued from Footnote 1) and not withdrawn, in accordance with the Delaware General Corporation Law) was thereupon canceled and converted into the right to receive $52.00 in cash, without interest (the "Merger Consideration"). As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any Shares. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $22.39 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-20 · Disposition to issuer · Disposed 8,342 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.06 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-20 · Disposition to issuer · Disposed 4,504 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $11.60 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-10-20 · Disposition to issuer · Disposed 12,287 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $12.94 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-10-20 · Disposition to issuer · Disposed 13,352 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $13.94 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-10-20 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-10-20 · Disposition to issuer · Disposed 15,723 · Balance 0 F4: At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Shares," and each such share, a "Share") (other than any such Shares (i) held by the Company as treasury stock or owned by Parent or Merger Sub, (ii) held by any subsidiary of the Company or Parent (other than Merger Sub) or (iii) as to which appraisal rights have been properly exercised,
F2: (Continued from Footnote 1) and not withdrawn, in accordance with the Delaware General Corporation Law) was thereupon canceled and converted into the right to receive $52.00 in cash, without interest (the "Merger Consideration"). As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any Shares.
F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
F4: At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 20, 2022 Filed Oct 24, 2022 19:01 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Disposition to issuerRestricted Stock Unit · Derivative | 15,723 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-034076 · doc4.xml · derivative · entry 7 FECZKO JOSEPH M · CIK 0001319874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,723 shares Expires not disclosed F4 · derivative.exercise_price: At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date. F4 · price: At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date. F4 · derivative.exercise_date: At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date. F4 · derivative.expiration_date: At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date. Read SEC document |
| October 20, 2022 Filed Oct 24, 2022 19:01 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Disposition to issuerStock Option · Derivative | 12,500 | Not disclosed Strike: $13.94 | Not disclosed |
DisclosureSEC source: 0000899243-22-034076 · doc4.xml · derivative · entry 6 FECZKO JOSEPH M · CIK 0001319874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. Read SEC document |
| October 20, 2022 Filed Oct 24, 2022 19:01 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Disposition to issuerStock Option · Derivative | 13,352 | Not disclosed Strike: $12.94 | Not disclosed |
DisclosureSEC source: 0000899243-22-034076 · doc4.xml · derivative · entry 5 FECZKO JOSEPH M · CIK 0001319874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,352 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. Read SEC document |
| October 20, 2022 Filed Oct 24, 2022 19:01 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Disposition to issuerStock Option · Derivative | 12,287 | Not disclosed Strike: $11.60 | Not disclosed |
DisclosureSEC source: 0000899243-22-034076 · doc4.xml · derivative · entry 4 FECZKO JOSEPH M · CIK 0001319874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,287 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. Read SEC document |
| October 20, 2022 Filed Oct 24, 2022 19:01 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Disposition to issuerStock Option · Derivative | 4,504 | Not disclosed Strike: $10.06 | Not disclosed |
DisclosureSEC source: 0000899243-22-034076 · doc4.xml · derivative · entry 3 FECZKO JOSEPH M · CIK 0001319874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,504 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. Read SEC document |
| October 20, 2022 Filed Oct 24, 2022 19:01 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Disposition to issuerStock Option · Derivative | 8,342 | Not disclosed Strike: $22.39 | Not disclosed |
DisclosureSEC source: 0000899243-22-034076 · doc4.xml · derivative · entry 2 FECZKO JOSEPH M · CIK 0001319874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,342 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. Read SEC document |
| October 20, 2022 Filed Oct 24, 2022 19:01 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Disposition to issuerCommon Stock | 148,127 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-034076 · doc4.xml · nonDerivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Shares," and each such share, a "Share") (other than any such Shares (i) held by the Company as treasury stock or owned by Parent or Merger Sub, (ii) held by any subsidiary of the Company or Parent (other than Merger Sub) or (iii) as to which appraisal rights have been properly exercised, F2 · price: (Continued from Footnote 1) and not withdrawn, in accordance with the Delaware General Corporation Law) was thereupon canceled and converted into the right to receive $52.00 in cash, without interest (the "Merger Consideration"). As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any Shares. Read SEC document |
| May 26, 2022 Filed May 31, 2022 21:30 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | GrantStock Option (right to buy) · Derivative | 8,342 | Not disclosed Strike: $22.39 | Not disclosed |
DisclosureSEC source: 0001209191-22-033036 · doc4.xml · derivative · entry 2 FECZKO JOSEPH M · CIK 0001319874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,342 Underlying: Common Stock · 8,342 shares Expires 2032-05-26 F4 · price: Not applicable. F3 · derivative.exercise_date: The option granted on May 26, 2022, vests on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company on such date. Read SEC document |
| May 26, 2022 Filed May 31, 2022 21:30 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | GrantRestricted Stock Units · Derivative | 15,723 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-033036 · doc4.xml · derivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,723 Underlying: Common Stock · 15,723 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F2 · derivative.exercise_date: The restricted stock units awarded on May 26, 2022, vests on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. F2 · derivative.expiration_date: The restricted stock units awarded on May 26, 2022, vests on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. Read SEC document |
| January 21, 2022 Filed Jan 25, 2022 20:03 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionStock Option (right to buy) · Derivative | 12,500 | Not disclosed Strike: $14.42 | Not disclosed |
DisclosureSEC source: 0001209191-22-004865 · doc4.xml · derivative · entry 4 FECZKO JOSEPH M · CIK 0001319874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2022-06-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: As of January 21, 2022, and prior to this transaction, the exercised options were fully vested. Read SEC document |
| January 21, 2022 Filed Jan 25, 2022 20:03 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $15.90 | Not disclosed |
DisclosureSEC source: 0001209191-22-004865 · doc4.xml · derivative · entry 3 FECZKO JOSEPH M · CIK 0001319874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2022-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: As of January 21, 2022, and prior to this transaction, the exercised options were fully vested. Read SEC document |
| January 21, 2022 Filed Jan 25, 2022 20:03 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionCommon Stock | 12,500 | $14.42 | $180,250.00 |
DisclosureSEC source: 0001209191-22-004865 · doc4.xml · nonDerivative · entry 2 FECZKO JOSEPH M · CIK 0001319874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2022 Filed Jan 25, 2022 20:03 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionCommon Stock | 25,000 | $15.90 | $397,500.00 |
DisclosureSEC source: 0001209191-22-004865 · doc4.xml · nonDerivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2021 Filed May 24, 2021 19:47 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | GrantStock Option (right to buy) · Derivative | 4,504 | Not disclosed Strike: $10.06 | Not disclosed |
DisclosureSEC source: 0001209191-21-035534 · doc4.xml · derivative · entry 2 FECZKO JOSEPH M · CIK 0001319874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,504 Underlying: Common Stock · 4,504 shares Expires 2031-05-20 F3 · price: Not applicable. F2 · derivative.exercise_date: The option granted on May 20, 2021, vests on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company on such date. Read SEC document |
| May 20, 2021 Filed May 24, 2021 19:47 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | GrantCommon Stock | 7,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-035534 · doc4.xml · nonDerivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,627 F1 · shares: The restricted stock awarded on May 20, 2021, vests on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company on such date. Read SEC document |
| May 21, 2020 Filed May 26, 2020 20:39 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | GrantStock Option (right to buy) · Derivative | 2,888 | Not disclosed Strike: $59.73 | Not disclosed |
DisclosureSEC source: 0001209191-20-032204 · doc4.xml · derivative · entry 2 FECZKO JOSEPH M · CIK 0001319874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,888 Underlying: Common Stock · 2,888 shares Expires 2030-05-21 F3 · price: Not applicable. F2 · derivative.exercise_date: The option granted on May 21, 2020, vests on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company on such date. Read SEC document |
| May 21, 2020 Filed May 26, 2020 20:39 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | GrantCommon Stock | 4,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-032204 · doc4.xml · nonDerivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,901 F1 · shares: The restricted stock awarded on May 21, 2020, vests on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company on such date. Read SEC document |
| May 23, 2019 Filed May 23, 2019 20:58 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | GrantStock Option (right to buy) · Derivative | 12,287 | Not disclosed Strike: $11.60 | Not disclosed |
DisclosureSEC source: 0001209191-19-032539 · doc4.xml · derivative · entry 2 FECZKO JOSEPH M · CIK 0001319874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,287 Underlying: Common Stock · 12,287 shares Expires 2029-05-23 F3 · price: Not applicable. F2 · derivative.exercise_date: The option granted on May 23, 2019, vests on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company on such date. Read SEC document |
| May 23, 2019 Filed May 23, 2019 20:58 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | GrantCommon Stock | 7,724 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-032539 · doc4.xml · nonDerivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,241 F1 · shares: The restricted stock awarded on May 23, 2019, vests on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company on such date. Read SEC document |
| May 21, 2018 Filed May 23, 2018 21:47 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | GrantStock Option (Right to buy) · Derivative | 13,352 | $0.00 Strike: $12.94 | $0.00 |
DisclosureSEC source: 0001209191-18-032798 · doc4.xml · derivative · entry 2 FECZKO JOSEPH M · CIK 0001319874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,352 Underlying: Common Stock · 13,352 shares Expires 2028-05-21 F2 · derivative.exercise_date: The option was granted on May 21, 2018. The award vests and becomes exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued employment or service relationship with the Company on such vesting date. Read SEC document |
| May 21, 2018 Filed May 23, 2018 21:47 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | GrantCommon Stock | 8,421 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-032798 · doc4.xml · nonDerivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,517 F1 · shares: The restricted stock was awarded on May 21, 2018, and 100% of the restricted stock will vest on May 21, 2019, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following the vesting date. Read SEC document |
| May 26, 2017 Filed May 30, 2017 19:37 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionRestricted Stock Units · Derivative | 20,362 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-036294 · doc4.xml · derivative · entry 3 FECZKO JOSEPH M · CIK 0001319874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,362 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F4 · derivative.exercise_date: 100% of the restricted stock units vested on May 26, 2017. Vested shares will be delivered to the Reporting Person within thirty (30) days following the vesting date. F4 · derivative.expiration_date: 100% of the restricted stock units vested on May 26, 2017. Vested shares will be delivered to the Reporting Person within thirty (30) days following the vesting date. Read SEC document |
| May 26, 2017 Filed May 30, 2017 19:37 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionCommon Stock | 20,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-036294 · doc4.xml · nonDerivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares were acquired upon vesting of restricted stock units awarded on May 26, 2016. Read SEC document |
| May 25, 2017 Filed May 30, 2017 19:37 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | GrantRestricted Stock Units · Derivative | 12,912 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-036294 · doc4.xml · derivative · entry 2 FECZKO JOSEPH M · CIK 0001319874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,912 Underlying: Common Stock · 12,912 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest on May 25, 2018, subject to the Reporting Person's continued service to the Company on such date. Vested shares will be delivered to the Reporting Person within thirty (30) days following the vesting date. F3 · derivative.expiration_date: 100% of the restricted stock units will vest on May 25, 2018, subject to the Reporting Person's continued service to the Company on such date. Vested shares will be delivered to the Reporting Person within thirty (30) days following the vesting date. Read SEC document |
| May 25, 2017 Filed Aug 1, 2017 18:27 UTC Amendment | ChemoCentryx, Inc. CCXI · Entity 122928 | Disposition to issuerRestricted Stock Units · Derivative | 12,912 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-046966 · doc4a.xml · derivative · entry 2 FECZKO JOSEPH M · CIK 0001319874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,912 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F1 · kind: The reporting person is amending the Form 4 originally filed to report restricted stock units awarded on May 25, 2017. The Form 4 should have reported the award as a restricted stock award. The restricted stock awarded on May 25, 2017, vests 100% on May 25, 2018, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following the vesting date. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F1 · derivative.exercise_date: The reporting person is amending the Form 4 originally filed to report restricted stock units awarded on May 25, 2017. The Form 4 should have reported the award as a restricted stock award. The restricted stock awarded on May 25, 2017, vests 100% on May 25, 2018, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following the vesting date. F1 · derivative.expiration_date: The reporting person is amending the Form 4 originally filed to report restricted stock units awarded on May 25, 2017. The Form 4 should have reported the award as a restricted stock award. The restricted stock awarded on May 25, 2017, vests 100% on May 25, 2018, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following the vesting date. Read SEC document |
| May 25, 2017 Filed Aug 1, 2017 18:27 UTC Amendment | ChemoCentryx, Inc. CCXI · Entity 122928 | GrantCommon Stock | 12,912 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-046966 · doc4a.xml · nonDerivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,096 F1 · kind: The reporting person is amending the Form 4 originally filed to report restricted stock units awarded on May 25, 2017. The Form 4 should have reported the award as a restricted stock award. The restricted stock awarded on May 25, 2017, vests 100% on May 25, 2018, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following the vesting date. Read SEC document |
| March 13, 2009 Filed Mar 16, 2009 20:50 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 951 | $14.54 | $13,827.54 |
DisclosureSEC source: 0000078003-09-000044 · fec1982.xml · derivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,354 Underlying: Common Stock · 951 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 26, 2009 Filed Mar 2, 2009 23:25 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 17,404 | $12.70 | $221,030.80 |
DisclosureSEC source: 0000078003-09-000030 · fec1967.xml · nonDerivative · entry 3 FECZKO JOSEPH M · CIK 0001319874 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 428,855 Read SEC document |
| February 26, 2009 Filed Mar 2, 2009 23:25 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 46,042 | $0.00 | $0.00 |
DisclosureSEC source: 0000078003-09-000030 · fec1967.xml · nonDerivative · entry 2 FECZKO JOSEPH M · CIK 0001319874 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,259 F2 · shares: The reported transaction constitutes the earn-out of Performance-Contingent Shares and Performance Shares. Read SEC document |
| February 26, 2009 Filed Mar 2, 2009 23:25 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 14,130 | $0.00 | $0.00 |
DisclosureSEC source: 0000078003-09-000030 · fec1967.xml · nonDerivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,217 F1 · shares: The reported transaction constitutes the grant of restricted stock units. Read SEC document |
| February 23, 2009 Filed Feb 25, 2009 12:03 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 5,326 | $13.27 | $70,676.02 |
DisclosureSEC source: 0000078003-09-000026 · fec1963.xml · nonDerivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,087 Read SEC document |
| December 31, 2008 Filed Jan 5, 2009 12:58 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 76 | $17.71 | $1,345.96 |
DisclosureSEC source: 0000078003-09-000004 · fec1945.xml · derivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,736 Underlying: Common Stock · 76 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 15, 2008 Filed Dec 16, 2008 23:51 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 81 | $16.63 | $1,347.03 |
DisclosureSEC source: 0000078003-08-000311 · fec1934.xml · derivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,660 Underlying: Common Stock · 81 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 26, 2008 Filed Dec 1, 2008 22:24 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 100 | $16.07 | $1,607.00 |
DisclosureSEC source: 0000078003-08-000300 · fec1923.xml · derivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,579 Underlying: Common Stock · 100 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 14, 2008 Filed Nov 17, 2008 21:44 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 578 | $16.28 | $9,409.84 |
DisclosureSEC source: 0000078003-08-000289 · fec1912.xml · derivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,479 Underlying: Common Stock · 578 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 31, 2008 Filed Nov 3, 2008 19:53 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 76 | $17.71 | $1,345.96 |
DisclosureSEC source: 0000078003-08-000271 · fec1901.xml · derivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,901 Underlying: Common Stock · 76 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 15, 2008 Filed Oct 16, 2008 18:50 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 80 | $16.27 | $1,301.60 |
DisclosureSEC source: 0000078003-08-000259 · fec1889.xml · derivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,825 Underlying: Common Stock · 80 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 30, 2008 Filed Oct 1, 2008 21:38 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 76 | $18.44 | $1,401.44 |
DisclosureSEC source: 0000078003-08-000248 · fec1877.xml · derivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,745 Underlying: Common Stock · 76 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 15, 2008 Filed Sep 16, 2008 18:00 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 67 | $18.05 | $1,209.35 |
DisclosureSEC source: 0000078003-08-000229 · fec1860.xml · derivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,669 Underlying: Common Stock · 67 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 29, 2008 Filed Sep 2, 2008 20:22 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 94 | $19.11 | $1,796.34 |
DisclosureSEC source: 0000078003-08-000218 · fec1849.xml · derivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,602 Underlying: Common Stock · 94 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 15, 2008 Filed Aug 19, 2008 16:27 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 449 | $19.97 | $8,966.53 |
DisclosureSEC source: 0000078003-08-000203 · fec1836.xml · derivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,508 Underlying: Common Stock · 449 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 31, 2008 Filed Aug 1, 2008 21:10 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 74 | $18.67 | $1,381.58 |
DisclosureSEC source: 0000078003-08-000186 · fec1823.xml · derivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,059 Underlying: Common Stock · 74 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 15, 2008 Filed Jul 16, 2008 18:25 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 72 | $17.58 | $1,265.76 |
DisclosureSEC source: 0000078003-08-000174 · fec1812.xml · derivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,985 Underlying: Common Stock · 72 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 30, 2008 Filed Jul 1, 2008 20:09 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 80 | $17.47 | $1,397.60 |
DisclosureSEC source: 0000078003-08-000164 · fec1802.xml · derivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,913 Underlying: Common Stock · 80 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 13, 2008 Filed Jun 16, 2008 20:34 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 82 | $17.99 | $1,475.18 |
DisclosureSEC source: 0000078003-08-000133 · fec1784.xml · derivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,833 Underlying: Common Stock · 82 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 30, 2008 Filed Jun 3, 2008 13:51 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 87 | $19.36 | $1,684.32 |
DisclosureSEC source: 0000078003-08-000119 · fec1780.xml · derivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,751 Underlying: Common Stock · 87 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 15, 2008 Filed May 16, 2008 18:06 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 441 | $20.08 | $8,855.28 |
DisclosureSEC source: 0000078003-08-000109 · fec1756.xml · derivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,664 Underlying: Common Stock · 441 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 30, 2008 Filed May 1, 2008 21:59 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 81 | $20.11 | $1,628.91 |
DisclosureSEC source: 0000078003-08-000092 · fec1750.xml · derivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,223 Underlying: Common Stock · 81 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 15, 2008 Filed Apr 17, 2008 19:30 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 114 | $20.71 | $2,360.94 |
DisclosureSEC source: 0000078003-08-000067 · fec1719.xml · derivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,142 Underlying: Common Stock · 114 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 31, 2008 Filed Apr 1, 2008 22:33 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 120 | $20.93 | $2,511.60 |
DisclosureSEC source: 0000078003-08-000056 · fec1709.xml · derivative · entry 1 FECZKO JOSEPH M · CIK 0001319874 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,028 Underlying: Common Stock · 120 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.